UA117506C2 - Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти - Google Patents

Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти

Info

Publication number
UA117506C2
UA117506C2 UAA201607988A UAA201607988A UA117506C2 UA 117506 C2 UA117506 C2 UA 117506C2 UA A201607988 A UAA201607988 A UA A201607988A UA A201607988 A UAA201607988 A UA A201607988A UA 117506 C2 UA117506 C2 UA 117506C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical preparation
acetic acid
intraocular pressure
lowering
acid compound
Prior art date
Application number
UAA201607988A
Other languages
English (en)
Ukrainian (uk)
Inventor
Нейвід Шамс
Хенк-Андре Крун
Хісасі Кавата
Норіко Кавабата
Original Assignee
Сантен Фармас'Ютікал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117506(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сантен Фармас'Ютікал Ко., Лтд. filed Critical Сантен Фармас'Ютікал Ко., Лтд.
Publication of UA117506C2 publication Critical patent/UA117506C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201607988A 2014-01-10 2015-01-08 Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти UA117506C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925882P 2014-01-10 2014-01-10
PCT/JP2015/050366 WO2015105144A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物を含む医薬製剤

Publications (1)

Publication Number Publication Date
UA117506C2 true UA117506C2 (uk) 2018-08-10

Family

ID=53520400

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201607988A UA117506C2 (uk) 2014-01-10 2015-01-08 Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти

Country Status (26)

Country Link
US (9) US9415038B2 (https=)
EP (3) EP3093018B1 (https=)
JP (7) JP5846338B2 (https=)
KR (1) KR101824829B1 (https=)
CN (2) CN108743587B (https=)
AU (1) AU2015205188B2 (https=)
BR (1) BR112016015763B8 (https=)
CA (1) CA2936026C (https=)
CL (1) CL2016001756A1 (https=)
DK (1) DK3093018T3 (https=)
EA (1) EA031734B1 (https=)
ES (2) ES2711091T3 (https=)
GE (2) GEP20186917B (https=)
HK (1) HK1223036A1 (https=)
HU (1) HUE041653T2 (https=)
IL (1) IL246447B (https=)
MX (1) MX370361B (https=)
MY (1) MY163235A (https=)
PH (1) PH12016501357B1 (https=)
PL (1) PL3093018T3 (https=)
PT (1) PT3093018T (https=)
SG (1) SG11201605653RA (https=)
TR (1) TR201902019T4 (https=)
TW (1) TWI598113B (https=)
UA (1) UA117506C2 (https=)
WO (1) WO2015105144A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
EP3093018B1 (en) 2014-01-10 2018-11-28 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
CA2935055C (en) 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
JP5951922B1 (ja) * 2014-12-12 2016-07-13 興和株式会社 水性組成物
CN107708738B (zh) * 2015-07-01 2022-03-25 参天制药株式会社 含有柠檬酸酯的贮库制剂
US20180200239A1 (en) * 2015-07-09 2018-07-19 Santen Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
WO2019065838A1 (ja) * 2017-09-29 2019-04-04 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
CA3086445A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Omidenepag combination
CN111526876A (zh) * 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
PL3681500T3 (pl) * 2018-04-24 2022-08-01 Allergan, Inc. Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
HRP20190509T1 (hr) 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) * 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
CA3099517C (en) * 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
KR101858373B1 (ko) 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
EP3093018B1 (en) * 2014-01-10 2018-11-28 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
CA2935055C (en) * 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound

Also Published As

Publication number Publication date
US11793798B2 (en) 2023-10-24
CN108743587B (zh) 2021-04-30
EP3093018A1 (en) 2016-11-16
US20150196541A1 (en) 2015-07-16
ES2834334T3 (es) 2021-06-17
EP3424503B1 (en) 2020-09-02
US10179127B2 (en) 2019-01-15
JP2024019479A (ja) 2024-02-09
EP3093018A4 (en) 2017-09-13
CA2936026A1 (en) 2015-07-16
NZ721620A (en) 2021-08-27
JP6491588B2 (ja) 2019-03-27
TW201609186A (zh) 2016-03-16
JP2025142352A (ja) 2025-09-30
ES2711091T3 (es) 2019-04-30
EA031734B1 (ru) 2019-02-28
US9415038B2 (en) 2016-08-16
CL2016001756A1 (es) 2017-05-12
PH12016501357B1 (en) 2020-12-09
GEAP201814239A (en) 2018-07-25
JPWO2015105144A1 (ja) 2017-03-23
JP7726542B2 (ja) 2025-08-20
KR101824829B1 (ko) 2018-02-01
CN108743587A (zh) 2018-11-06
IL246447A0 (en) 2016-08-31
EP3424503A1 (en) 2019-01-09
TWI598113B (zh) 2017-09-11
US20250235439A1 (en) 2025-07-24
HUE041653T2 (hu) 2019-05-28
US20240000763A1 (en) 2024-01-04
US20190105310A1 (en) 2019-04-11
JP2021006593A (ja) 2021-01-21
US20160324838A1 (en) 2016-11-10
BR112016015763B8 (pt) 2020-09-15
MY163235A (en) 2017-08-30
EA201691402A1 (ru) 2016-10-31
PL3093018T3 (pl) 2019-05-31
US12295946B2 (en) 2025-05-13
MX370361B (es) 2019-12-10
TR201902019T4 (tr) 2019-03-21
CN105899209A (zh) 2016-08-24
HK1223036A1 (zh) 2017-07-21
US20200289483A1 (en) 2020-09-17
JP5846338B2 (ja) 2016-01-20
US20220054466A1 (en) 2022-02-24
KR20160101030A (ko) 2016-08-24
AU2015205188A1 (en) 2016-07-14
GEP20186917B (en) 2018-11-12
MX2016009063A (es) 2016-09-28
SG11201605653RA (en) 2016-08-30
JP7087040B2 (ja) 2022-06-20
EP3750541A1 (en) 2020-12-16
CN105899209B (zh) 2018-09-11
WO2015105144A1 (ja) 2015-07-16
IL246447B (en) 2020-06-30
JP2016027060A (ja) 2016-02-18
JP2022111280A (ja) 2022-07-29
USRE48183E1 (en) 2020-09-01
AU2015205188B2 (en) 2019-11-14
JP6785330B2 (ja) 2020-11-18
JP2019108363A (ja) 2019-07-04
EP3093018B1 (en) 2018-11-28
US10702511B2 (en) 2020-07-07
BR112016015763B1 (pt) 2020-09-01
PH12016501357A1 (en) 2016-08-15
PT3093018T (pt) 2019-01-10
US20180169079A1 (en) 2018-06-21
US11197849B2 (en) 2021-12-14
DK3093018T3 (en) 2019-02-04
US9943510B2 (en) 2018-04-17
JP7402922B2 (ja) 2023-12-21
CA2936026C (en) 2022-04-19

Similar Documents

Publication Publication Date Title
UA117506C2 (uk) Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
EP4700016A3 (en) Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
MX2015014672A (es) Composicion farmaceutica oral para prevenir o tratar el sindrome de ojo seco que comprende rebamipida o un profarmaco de la misma.
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
MX2019007213A (es) Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.
EP4338751A3 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
FI3519050T3 (fi) Koostumuksia silmätautien hoitamiseksi
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.